Immunity to cross-reactive serotypes induced by pneumococcal conjugate vaccines in infants

Journal of Infectious Diseases

Volumn 180, Issue 5, 1999, Pages 1569-1576

  Yu, Xinhong ^a   Gray, Barry ^b   Chang, Swei Ju ^c   Ward, Joel I ^c   Edwards, Kathryn M ^d   Nahm, Moon H ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b Gibbs Cancer Center and Research Institute   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CROSS REACTING ANTIBODY; IMMUNOGLOBULIN G; PNEUMOCOCCUS VACCINE;

ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CROSS INFECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN EXPERIMENT; IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; INFANT; NORMAL HUMAN; OPSONIZATION; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS PNEUMONIAE;

ADULT; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; CARBOHYDRATE SEQUENCE; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN G; INFANT; MOLECULAR SEQUENCE DATA; OPSONIN PROTEINS; PHAGOCYTOSIS; PNEUMOCOCCAL INFECTIONS; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES, CONJUGATE;

EID: 0032722371     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315096     Document Type: Article

References (30)

1. 1. Fedson DS, Musher DM. Pneumococcal vaccine. In: Plotkin SA, Mortimer EA Jr, eds. Vaccines. 2nd ed. Philadelphia: WB Saunders, 1994:517-64.
2. 2. Austrian R, Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964;60:759-76.
3. 3. Mufson MA, Oley G, Hughey D. Pneumococcal disease in a medium-sized community in the United States. JAMA 1982;248:1486-9.
4. 4. Breiman RF, Butler JC, Tenover FC, Elliott JA, Facklam RR. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994;271:1831-5.
5. 5. Hofmann J, Cetron MS, Farley MM, et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995;333:481-6.
6. 6. Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol 1995;33:2759-62.
7. 7. Robbins JB, Austrian R, Lee CJ, et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 1983;148: 1136-59.
8. 8. Kniskern PJ, Marburg S. Conjugation: design, chemistry, and analysis. In: Ellis RW, Granoff DM, eds. Infectious disease and therapy. New York: Marcel Dekker, 1994:37-69.
9. 9. Siber GR. Pneumococcal disease: prospects for a new generation of vaccines. Science 1994;265:1385-7.
10. 10. Rennels MB, Edwards KM, Keyserling A, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 1998;101:604-11.
11. 11. Kenne L, Lindberg B. Bacterial polysaccharides. In: Aspinall GO, ed. The polysaccharides. New York: Academic Press, 1983:287-363.
12. 12. Katzenellenbogen E, Jennings HJ. Structural determination of the capsular polysaccharide of Streptococcus pneumoniae type 19A(57). Carbohydr Res 1983;124:235-45.
13. 13. Daum RS, Hogerman D, Rennels MB, et al. Infant immunization with pneumococcal CRM197 vaccines: effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines. J Infect Dis 1997;176:445-55.
14. 14. Dagan R, Melamed R, Muallem M, et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 1996;174:1271-8.
15. 15. Gray BM. Opsonophagocidal activity in sera from infants and children immunized with Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate). Pediatrics 1990;85:694-7.
16. 16. Nahm MH, Olander JV, Magyarlaki M. Identification of cross-reactive antibodies with low opsonophagocytic activity for Streptococcus pneumoniae. J Infect Dis 1997;176:698-703.
17. 17. Quataert SA, Kirch CS, Wiedl LJQ, et al. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin Diagn Lab Immunol 1995;2:590-7.
18. 18. Brown EJ, Hosea SW, Hammer CH, Burch CG, Frank MM. A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremia. J Clin Invest 1982;69: 85-98.
19. 19. Joiner KA, Brown EJ, Frank MM. Complement and bacteria. Annu Rev Immunol 1984;2:461-91.
20. 20. Loeb MR, Anderson P, Porcelli S. Specificity problems with the ELISA for serotype-specific Streptococcus pneumoniae (Spn) antibodies. Pediatr Res 1996;39:177A.
21. 21. Coughlin RT, White AC, Anderson CA, Carlone GM, Klein DL, Treanor J. Characterization of pneumococcal specific antibodies in healthy unvaccinated adults. Vaccine 1998;16:1761-7.
22. 22. Yu X, Sun Y, Frasch CE, Conception N, Nahm MH. Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic. Clin Diagn Lab Immunol 1999;6:519-24.
23. 23. Peltola H, Kayhty H, Virtanen M, Makela PH. Prevention of Haemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med 1984;310:1561-6.
24. 24. Murphy TV, Osterholm MT, Piet MPJ, et al. Prospective surveillance of Haemophilus influenzae type b disease in Dallas County, Texas, and in Minnesota. Pediatrics 1987;79:173-80.
25. 25. Baker CJ, Kasper DL, Edwards MS, Schiffman G. Influence of preimmunization antibody levels on the specificity of the immune response to related polysaccharide antigens. N Engl J Med 1980;303:173-8.
26. 26. Mbelle N, Wasas A, Huebner R, Kimura A, Chang I, Klugman K. Immunogenicity and impact on carriage of 9-valent pneumococcal conjugate vaccine given to infants in Soweto, South Africa [abstract LB-21]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997.
27. 27. Dagan R, Givon N, Yagupsky P, et al. Effect of a 9-valent pneumococcal vaccine conjugated to CRM197 (PneCRM9) on nasopharyngeal carriage of vaccine type and non-vaccine type S. pneumoniae (Pne) strains among day care center (DCC) attendees [abstract G-52]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 1998.
28. 28. Lucas AH, Azmi FH, Mink CM, Granoff DM. Age-dependent V region expression in the human antibody response to the Haemophilus influenzae type b polysaccharide. J Immunol 1993;150:2056-61.
29. 29. Hetherington SV, Rutkowski AF. Antibody affinity in infants after immunization with conjugated capsular polysaccharide from Haemophilus influenzae type b. J Infect Dis 1990;162:1185-8.
30. 30. Sniadack DH, Schwartz B, Lipman H, et al. Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children - implications for vaccine strategies. Pediatr Infect Dis J 1995;14:503-10.